PSA/IL-2/GM-CSF vaccine - Oncbiomune

Drug Profile

PSA/IL-2/GM-CSF vaccine - Oncbiomune

Alternative Names: ProscaVax; Prostatac; Prostate cancer vaccine - Oncbiomune

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncbiomune; United States Army
  • Developer OncBioMune
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 15 Sep 2017 Updated safety data from a phase Ia trial in Prostate cancer released by OncBioMune
  • 01 Sep 2017 OncBioMune Pharmaceuticals's protocol for a phase II trial in Prostate cancer (Newly diagnosed, First-line therapy, Early-stage disease) is under review in Israel
  • 27 Jun 2017 Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) Mexico approves clinical trial application for PSA/IL-2/GM-CSF vaccine in Prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top